Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Can-Fite BioPharma ( (CANF) ).
On January 27, 2026, Can-Fite BioPharma announced it will convene a Special General Meeting of Shareholders on March 3, 2026 in Ramat Gan, Israel, where investors will vote on electing Ilan Tamir as an external director for a three‑year term, approving new stock option grants for directors (excluding chairperson Dr. Pnina Fishman), and adopting an updated three‑year compensation policy in line with Israeli corporate law. The move follows a January 21, 2026 notice from NYSE American that Can-Fite is out of compliance with audit committee composition rules after an independent director’s resignation; the proposed election of Tamir is expected to restore the required number of independent audit committee members, avoiding any immediate impact on the company’s NYSE American listing and underscoring management’s efforts to quickly address governance deficiencies and reassure ADS and ordinary shareholders.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd., based in Ramat Gan, Israel, is a foreign private issuer listed on the NYSE American under the symbol “CANF.” The company operates in the biopharmaceutical sector and its securities include ordinary shares and American Depositary Shares, attracting both Israeli and international investors who are subject to U.S. and Israeli corporate governance and securities regulations.
Average Trading Volume: 517,611
Technical Sentiment Signal: Sell
Current Market Cap: $5.94M
For detailed information about CANF stock, go to TipRanks’ Stock Analysis page.